Drug intelligence / Profile preview

RY109

Development stage: Preclinical
Lead developer: Reyon Pharmaceutical
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

RY109 is a plasmid DNA (pDNA)-based therapeutic vaccine being developed by Reyon Pharm for the treatment of ovarian cancer. As a therapeutic vaccine, it is designed to stimulate the patient's immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. The drug utilizes a DNA plasmid platform to deliver genetic material into host cells, which then express the target antigens to induce a specific T-cell mediated immune response. RY109 is currently in the preclinical stage of development as part of Reyon Pharm's oncology pipeline.

Beyond the preview

Go deeper on RY109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RY109.

Explore the full profile